Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: A reasonable regimen for the community-based clinic?

Cancer Investigation

Volumn 25, Issue 1, 2007, Pages 27-31

  Berry, William ^a   Elkordy, Maha ^a   O'Rourke, Mark ^a   Khan, Myrna ^a   Asmar, Lina ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Advanced; Carboplatin; Carcinoma; Paclitaxel; Unknown primary

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLURRED VISION; CANCER GROWTH; CANCER OF UNKNOWN PRIMARY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; FEMALE; HEARTBURN; HUMAN; HYPOKALEMIA; LEUKOPENIA; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SORE THROAT; SURVIVAL TIME; TOXICITY TESTING; VOMITING; WEAKNESS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 33947262183     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900601130656     Document Type: Article

References (14)

1. Briasoulis, E.; Pavlidis, N. Cancer of unknown primary origin. Oncologist 1997, 2 (3), 142-152.
2. American Cancer Society. Detailed guide: what are the key statistics for cancer of unknown primary. January 2004 update. Available online at: http://www.cancer.org/docroot/CRI/content/ CRI_2_4_1X_What_are_the_key_statistics_for_cancer_of_unknown_primary_58.asp? sitearea=. [accessed June 15, 2005].
3. Blaszyk, H.; Hartmann, A.; Bjornsson, J. Cancer of unknown primary: clinicopathologic correlations. APMIS 2003. 111 (12), 1089-1094.
4. Hainsworth, J.D.; Johnson, D.H.; Greco, F.A. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J. Clin. Oncol. 1992, 10 (6), 912-922.
5. Hanauske, A.R.; Clark, G.M.; Von Hoff, D.D. Adenocarcinoma of unknown primary: a retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system. Invest. New Drugs 1995, 13 (1), 43-49.
6. Greco, F.A.; Hainsworth, J.D. The evolving role of paclitaxel for patients with carcinoma of unknown primary site. Sem. Oncolog. 1999, 26 (1 Suppl. 2), 129-133.
7. Hainsworth, J.D.; Erland, J.B.; Kalman, L.A.; et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J. Clin. Oncol. 1997, 15 (6), 2385-2393.
8. Briasoulis, E.; Kalafonos, H.; Bafaloukas, D.; et al. Carboplatin plus paclitaxel in unknown primary carcinoma, a phase II Helenic Cooperative Oncology Group Study. J. Clin. Oncol. 2000, 18 (17), 3101-3107.
9. Greco, F.A.; Burris, H.A. 3rd; Litchy, S.; et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J. Clin. Oncol. 2002, 20 (6), 1651-1656.
10. Greco, F.A.; Gray, J.; Burris, H.A. 3rd; Erland, J.B.; Morrissey, L.H.; Hainsworth, J.D. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J. 2001, 7 (3), 203-212.
11. Culine, S.; Lortholary, A.; Voigt, J.; et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEF-CAPI 01). J. Clin. Oncol. 2003, 21 (18), 3479-3482.
12. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48; 1979.
13. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53, 457-481.
14. Culine, S.; Kramar, A.; Saghatchian, M.; et al. Development and validation of a prognsotic model to predict the length of survival in patients with carcinomas of an unknown primary site. J. Clin. Oncol. 2002, 20 (24), 4679-4683.